{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:48:31Z","timestamp":1777916911084,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T00:00:00Z","timestamp":1228867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T00:00:00Z","timestamp":1228867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nephron"],"abstract":"<jats:p>A 41-year-old hemodialyzed woman developed ascites and was found to have secondary iron overload. The dose ofadministered iron was approximately 11\u201312 g, and her serum ferritin level was 15,000 ng\/ml (15,000 \u03bcg\/l). There were no signs of congestive heart failure, fluid overload, or liver cirrhosis. A program of weekly phlebotomy combined with recombinant human erythropoietin (rhEPO) therapy was tried to eliminate the iron congestion. After 9 months of this therapy, about 5 g of iron had been removed. The ascites completely disappeared, and her serum ferritin level fell to 5,800 ng\/ml (5,800 \u03bcg\/l). This suggests that such combined therapy would be useful when iron overload must be corrected rapidly. Before therapy, the sterile ascitic fluid showed exudative characteristics with 3.7 g\/dl (37 g\/l) of total protein. The serum-ascites albumin difference was 0.6 g\/dl (6 g\/l), and the fluid contained 1,400 inflammatory cells\/mm3 (1.4 \u00d7 109\/l). Notably, the serum-ascites albumin difference increased in parallel with iron elimination. These findings suggested that iron deposition may have played a role in changing the permeability of the peritoneum, or in impairing lymphatic drainage, both of which are presumed to be pathogenetic factors of nephrogenic ascites.<\/jats:p>","DOI":"10.1159\/000185954","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T09:35:10Z","timestamp":1228988110000},"page":"210-213","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of a Patient with End-Stage Renal Disease, Severe Iron Overload and Ascites by Weekly Phlebotomy Combined with Recombinant Human Erythropoietin"],"prefix":"10.1159","author":[{"given":"Shinsuke","family":"Nomura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gengo","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Machiko","family":"Karai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2008,12,10]]},"container-title":["Nephron"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/185954","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000185954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:59:51Z","timestamp":1777658391000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000185954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,10]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000185954","archive":["Portico"],"relation":{},"ISSN":["1660-8151","2235-3186"],"issn-type":[{"value":"1660-8151","type":"print"},{"value":"2235-3186","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,10]]}}}